Oklo Inc.

06/17/2026

At Oklo, our isotope work is personal.

Some members of our team have spent decades advancing the technology that shows up in critical moments, from disease diagnosis and cancer care to space exploration.

That dedication shows up in how Oklo is built, and shapes how we think about deployment, bringing power, fuel, and isotopes together into a single platform designed to deliver more from nuclear technology.

Isotopes support everyday life in ways that most people never see. ...

06/10/2026

Two sites. Two reactors. One integrated nuclear platform.

At Idaho National Laboratory, construction is advancing on Oklo’s first commercial Aurora powerhouse, bringing clean, reliable power closer to deployment. Our team and Kiewit Corporation have removed more than 65,000 cubic yards of material to prepare the reactor foundation, roughly enough to fill 20 Olympic swimming pools.

In Texas, our Groves isotope test reactor is approaching criticality, a key step toward unlocking future production of critical materials used in medicine, industry, and space applications. Built in less than a year, Groves is helping Oklo develop the real-world experience, supply chains, workforce capabilities, and operational know-how needed to make advanced nuclear deployment faster, more repeatable, and more scalable.

Together, these projects reflect how Oklo is executing across power, fuel, and isotopes simultaneously.

This is what deployment looks like.

Watch the latest progress.

Two sites. Two reactors. One integrated nuclear platform.In less ...

06/08/2026

Oklo’s vertical integration sets us apart. We build, own, and operate our facilities across our three business lines of power, fuel, and isotopes.

Today, we're deepening that integration with the acquisition of ARMEC, bringing more than two decades of operating experience and a team of approximately 40 engineers, fabricators, machinists, welders, and technical personnel with extensive nuclear experience directly into our reactor and fuel-manufacturing programs.

Advanced nuclear deployment requires manufacturing depth. ARMEC strengthens ours.

Read more ->
https://oklo.com/newsroom/news-details/2026/Oklo-Acquires-ARMEC-to-Expand-Vertically-Integrated-Manufacturing-Capabilities-for-Advanced-Reactor-and-Fuel-Manufacturing-Programs/default.aspx

05/29/2026

Oklo CEO Jacob DeWitte joined Maria Bartiromo on Mornings with Maria to discuss the momentum behind advanced nuclear and the work Oklo is doing to deliver clean, reliable power and critical isotopes.

From advancing negotiations under the Department of Energy’s Surplus Plutonium Utilization Program to partnering with Meta to support growing data center demand in Ohio and approaching criticality with our isotope test reactor in Texas, Oklo is putting the pieces in place to accelerate deployment across its power, fuel, and isotope businesses.

Watch the full interview ->

Oklo CEO Jacob DeWitte joins 'Mornings with Maria' to discuss the rising AI energy demand, a major Meta partnership and President Donald Trump's nuclear agenda are accelerating America's nuclear future.

05/20/2026

In less than two months, Oklo’s isotope test reactor will go critical.

We’re building, iterating, and executing in real time across power, fuel, and isotopes.

Follow our journey: https://www.youtube.com/

04/21/2026

on CNBC, Oklo CEO Jacob DeWitte discussed the White House’s push to deploy nuclear systems in space.

The challenge isn’t whether it’s possible. It’s whether we can build the infrastructure fast enough.

At Oklo, we’re building the systems needed to deliver at the speed this moment demands.

Full interview:

Jacob DeWitte, Oklo CEO, joins 'The Exchange' to discuss nuclear energy's impact on markets, plans in space and future growth.

04/01/2026

At Oklo, we don’t celebrate women for one month, we build with them every day.

Women across our company are designing reactors, leading regulatory strategy, producing life-saving isotopes, and strengthening the systems communities will rely on for decades.

We are proud of the women building the future of power here and of the example they set for the next generation.

03/25/2026

Oklo co-founder and CEO Jacob DeWitte has been appointed to the President’s Council of Advisors on Science and Technology (PCAST), which advises the White House on priorities shaping U.S. leadership in science and technology.

DeWitte joins leaders from across the industry to help inform how the United States approaches emerging technologies and the infrastructure needed to support them.

As energy demand grows and the U.S. works to strengthen domestic supply chains, decisions about deploying reliable, affordable power are becoming more immediate. Nuclear energy will play a critical role in delivering clean, abundant energy while reducing reliance on foreign sources. Oklo is working to deploy advanced nuclear technologies across power generation, fuel supply, and isotope production to help meet this need.

Today, President Donald J. Trump appointed the first members to his President’s Council of Advisors on Science and Technology (PCAST). Established by

03/18/2026

Meet Groves — Oklo's isotopes test reactor, under construction in Texas.

Isotopes power some of the most critical technologies in modern medicine, from early cancer detection to targeted therapies that deliver treatment directly to tumors. Millions of Americans depend on them. Nearly all of that supply comes from overseas.

Oklo is building here. And we're reaching criticality by July 4th.

Stay tuned.

Meet Groves — Oklo's isotopes test reactor, under construction in Lockhart, Texas.Isotopes power some of the most critical technologies in modern medicine, f...

03/17/2026

Oklo has received its first U.S. Nuclear Regulatory Commission license.

Through our subsidiary Atomic Alchemy, this license enables the handling, processing, and distribution of isotope materials — supporting initial commercial production in the United States.

50 million nuclear medicine procedures are performed every year. Nearly all of the isotopes that make them possible come from aging reactors outside the United States — many expected to retire within the decade.

And nuclear medicine is just one of many applications for these critical materials.

Demand is rising. Supply is shrinking. The consequences of a shortage are serious: delayed cancer treatments, constrained research, and bottlenecks in industries that rely on nuclear technologies.

Oklo is working to change that.

Swipe through to learn more, and see the full press release below.

https://oklo.com/newsroom/news-details/2026/Oklos-Atomic-Alchemy-Granted-U-S--Nuclear-Regulatory-Commission-License-for-Isotope-Material/default.aspx